Serum immunoreactive bone sialoprotein as a new marker of bone turnover in metabolic and malignant bone disease

M J Seibel, H W Woitge, M Pecherstorfer, M Karmatschek, E Horn, H Ludwig, F P Armbruster, R Ziegler

Research output: Journal article (peer-reviewed)Journal article

110 Citations (Scopus)


Bone sialoprotein (BSP) is a phosphorylated glycoprotein with a M(r) of 70-80 kDa that accounts for approximately 5-10% of the noncollagenous proteins of bone. Due to its relatively restricted distribution to mineralized tissues, BSP may serve as a potential marker of bone metabolism. Employing a recently developed RIA, serum BSP was measured in 133 healthy subjects, aged 20-80 yr, and in patients with primary hyperparathyroidism (pHPT; n = 26), Paget's disease of bone (PD; n = 14), untreated multiple myeloma (MM; n = 32), and breast cancer with bone metastases (BC; n = 19). Results were compared to clinical and laboratory data, including serum total alkaline phosphatase as a marker of bone formation, and the urinary cross-links pyridinoline (PYD) and deoxypyridinoline (DPD) as markers of bone resorption. In healthy adults, serum BSP values ranged between 5.0-21.6 ng/mL (5-95% interval), with a median of 10.5 ng/mL (total group). In healthy females, a linear correlation was found between serum BSP and age (r = 0.51; P < 0.001), with significantly higher values in postmenopausal than in premenopausal women (13.3 +/- 4.8 vs. 9.0 +/- 3.8; P < 0.01). In the healthy group, BSP values did not change with body mass index, lumbar bone mineral density, serum calcium, serum creatinine, or serum total alkaline phosphatase levels. In contrast, a weak, but significant, correlation was observed between serum BSP and the urinary excretion of PYD and DPD. Compared to those in healthy controls, serum BSP levels were significantly higher in patients with pHPT, PD, MM, or BC (P < 0.01 for all groups). These differences remained after analyses were adjusted for age and sex. In pHPT, serum BSP levels were closely correlated to urinary PYD and DPD (r = 0.87 and 0.83, respectively; P < 0.01), whereas in PD, no correlation was observed between any of the bone markers. Serum BSP levels were highest in patients with MM, and there was a significant difference between early and advanced stages of the disease (30.2 +/- 8.0 vs. 64.3 +/- 6.8; P < 0.01). In a subgroup of 15 patients with metastatic BC, iv bisphosphonate treatment resulted in a rapid reduction of serum BSP levels to 40% of the baseline values within 4 days of treatment. In conclusion, BSP appears to be a sensitive marker of bone turnover, and the present data suggest that its serum levels predominantly reflect processes related to bone resorption.

Original languageEnglish
Pages (from-to)3289-94
Number of pages6
JournalJournal of Clinical Endocrinology and Metabolism
Issue number9
Publication statusPublished - Sept 1996
Externally publishedYes


  • Adult
  • Aged
  • Aged, 80 and over
  • Alkaline Phosphatase/blood
  • Amino Acids/urine
  • Biomarkers
  • Bone Density
  • Bone Diseases/blood
  • Bone Resorption
  • Breast Neoplasms/blood
  • Female
  • Humans
  • Hyperparathyroidism/blood
  • Integrin-Binding Sialoprotein
  • Middle Aged
  • Multiple Myeloma/blood
  • Osteitis Deformans/blood
  • Radioimmunoassay
  • Reference Values
  • Sialoglycoproteins/blood


Dive into the research topics of 'Serum immunoreactive bone sialoprotein as a new marker of bone turnover in metabolic and malignant bone disease'. Together they form a unique fingerprint.

Cite this